Home›Trial›NCT07134088
🔬NCT07134088Phase 1Phase 2RECRUITING

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Study Summary

The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

Conditions
Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Interventions / Drugs
Blinatumomab
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment104 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.158271+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.